Jeremy Veenstra-Vanderweele, MD
Mortimer D. Sackler, M.D. Associate Professor of Psychiatry
Dr. Veenstra-VanderWeele is a child and adolescent psychiatrist who uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism spectrum disorder (ASD) and pediatric obsessive-compulsive disorder (OCD).
As a predoctoral fellow, medical student, and resident, he trained in human molecular genetics in the laboratory of Edwin H. Cook at the University of Chicago. He expanded his research experience with a postdoctoral research fellowship in molecular neuroscience with Randy Blakely and Jim Sutcliffe at Vanderbilt University, with the goal to develop mouse models of social dysfunction and repetitive behavior.
Currently, his molecular lab focuses on the serotonin, oxytocin and glutamate systems in genetic mouse models related to ASD and OCD. While developing a molecular neuroscience research program, he also built a clinical/translational research program to study new treatments for ASD and Fragile X Syndrome. He moved both arms of his research program to Columbia University, the New York State Psychiatric Institute, and NewYork-Presbyterian Hospital Center for Autism and the Developing Brain in 2014 to continue to pursue novel treatments for children with these challenging conditions.
The Veenstra-VanderWeele lab is focused on understanding the molecular underpinnings of autism spectrum disorder and obsessive compulsive disorder, with the goal of developing novel treatments that benefit children.
The lab is dedicated to helping children with autism spectrum disorder (ASD) or obsessive compulsive disorder (OCD) and their families. We are approaching this goal using a variety of techniques, from animal models to research in adults with ASD. The majority of our efforts go toward developing and studying mouse models to understand the relationship between ASD or OCD risk factors and the resulting changes in brain and behavior. We are also working to translate laboratory research findings into novel treatments for children and adults with autism spectrum disorders or related syndromal disorders.